Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 2/20 | 0.41 |
| ▸ | DRD1 | P21728 | 2/20 | 0.37 |
| ▸ | AKT1S1 | Q96B36 | 7/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 5/20 | 0.34 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.33 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.33 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.33 |
| ▸ | RET | P07949 | 2/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.33 |
| ▸ | FLT1 | P17948 | 2/20 | 0.33 |
| ▸ | LTK | P29376 | 2/20 | 0.33 |
| ▸ | GRK5 | P34947 | 2/20 | 0.33 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.33 |
| ▸ | CDK8 | P49336 | 2/20 | 0.33 |
| ▸ | CDK7 | P50613 | 2/20 | 0.33 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.33 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17041848 | 0.89 | UHRF1 (0.41) | NNMTDRD1AKT1S1KDRCHEK1 | |
| SCHEMBL795294 | 0.75 | DRD1 (0.49) | NNMTDRD1AKT1S1MKNK1KDR | |
| SCHEMBL30159359 | 0.75 | DRD1 (0.49) | NNMTDRD1AKT1S1MKNK1KDR | |
| SCHEMBL21362939 | 0.71 | PRKDC (0.34) | KDR | |
| SCHEMBL2606409 | 0.71 | KDR (0.50) | NNMTDRD1AKT1S1MKNK1KDR | |
| SCHEMBL3803152 | 0.71 | NNMT (0.44) | NNMTDRD1AKT1S1MKNK1KDR | |
| SCHEMBL12832924 | 0.70 | MKNK1 (0.45) | NNMTDRD1AKT1S1MKNK1KDR | |
| SCHEMBL2600057 | 0.70 | DRD1 (0.49) | NNMTDRD1AKT1S1MKNK1KDR | |
| SCHEMBL16812277 | 0.70 | NNMT (0.41) | NNMTDRD1AKT1S1MKNK1KDR | |
| SCHEMBL24773047 | 0.70 | NOTUM (0.39) | DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286943-A1 | IL-17A MODULATORS | SANOFI (FR) | 2023-09-14 | — | — | US | disclosed |
| US-20230227427-A1 | IL-17A MODULATORS | SANOFI (FR) | 2023-07-20 | — | — | US | disclosed |
| US-20230227427-A1 | IL-17A MODULATORS | SANOFI (FR) | 2023-07-20 | — | — | US | disclosed |
| US-20180072757-A1 | Novel Heterocyclic Derivatives as Modulators of Kinase Activity | MERCK PATENT GMBH (DE) | 2018-03-15 | — | — | US | disclosed |
| US-9850255-B2 | Heterocyclic derivatives as modulators of kinase activity | MERCK PATENT GMBH (DE) | 2017-12-26 | — | — | US | disclosed |
| US-9580443-B2 | Heterocyclic derivatives as modulators of kinase activity | MERCK PATENT GMBH (DE) | 2017-02-28 | — | — | US | disclosed |
| US-9580443-B2 | Heterocyclic derivatives as modulators of kinase activity | MERCK PATENT GMBH (DE) | 2017-02-28 | — | — | US | disclosed |
| US-20170015679-A1 | Novel Heterocyclic Derivatives as Modulators of Kinase Activity | MERCK PATENT GMBH (DE) | 2017-01-19 | — | — | US | disclosed |
| US-9315517-B2 | Imidazol-piperidinyl derivatives as modulators of kinase activity | MERCK PATENT GMBH (DE) | 2016-04-19 | — | — | US | disclosed |
| US-20150274750-A1 | Novel Heterocyclic Derivatives as Modulators of Kinase Activity | MERCK PATENT GMBH (DE) | 2015-10-01 | — | — | US | disclosed |
| US-20150239902-A1 | Novel Imidazol-piperidinyl Derivatives as Modulators of Kinase Activity | MERCK PATENT GMBH (DE) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227427-A1 | IL-17A MODULATORS | IL17A, IL2, IL15 | NNMT 2352/4885DRD1 4365/4885AKT1S1 4051/4885 |
| US-20170015679-A1 | Novel Heterocyclic Derivatives as Modulators of Kinase Activity | CDK2, MAP4K3, MAP4K2 | NNMT 2367/4885DRD1 3465/4885AKT1S1 372/4885 |
| US-20150274750-A1 | Novel Heterocyclic Derivatives as Modulators of Kinase Activity | CDK2, MAP4K3, MAP4K2 | NNMT 2367/4885DRD1 3465/4885AKT1S1 372/4885 |
| US-20150239902-A1 | Novel Imidazol-piperidinyl Derivatives as Modulators of Kinase Activity | MAP4K2, MAP4K3, MAP3K4 | NNMT 2162/4885DRD1 3782/4885AKT1S1 583/4885 |
| US-20230286943-A1 | IL-17A MODULATORS | IL17A, IL2, IL15 | NNMT 2352/4885DRD1 4365/4885AKT1S1 4051/4885 |
| US-20180072757-A1 | Novel Heterocyclic Derivatives as Modulators of Kinase Activity | CDK2, MAP4K3, MAP4K2 | NNMT 2367/4885DRD1 3465/4885AKT1S1 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.